Press release
Stargardt Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Asc
Stargardt Disease Clinical Trials
According to DelveInsight, the Stargardt Disease pipeline features over 20 leading companies actively developing more than 20 therapeutic candidates for the treatment of Stargardt Disease.
Stargardt Disease Overview:
Stargardt disease is an inherited genetic disorder caused by mutations in both copies of the ABCA4 gene, one from each parent. These mutations result in the abnormal accumulation of lipofuscin, a cellular waste product, in the retina. Normally, the retina can efficiently clear this waste, but in Stargardt disease, this process is impaired, leading to retinal cell damage and progressive vision loss. The severity of the condition varies depending on the specific ABCA4 mutations, with some individuals experiencing more pronounced vision impairment than others. Regardless of severity, the core mechanism involves defective ABCA4 genes disrupting retinal metabolism, causing toxic lipofuscin buildup and gradual retinal degeneration. Research into these genetic variations is ongoing and may enable the development of targeted therapies.
Stargardt disease primarily affects central vision, leading to blurriness, visual distortion, or dark spots due to damage to the macula, which is critical for sharp vision. It can also impair color perception and the ability to adapt to changes in lighting.
Request for a detailed insights report on Stargardt Disease pipeline insights [https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Stargardt Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Stargardt Disease Therapeutics Market.
Key Takeaways from the Stargardt Disease Pipeline Report
*
DelveInsight's Stargardt Disease pipeline report highlights an active and evolving landscape, with over 20 companies developing more than 20 therapeutic candidates for the treatment of Stargardt Disease.
*
Leading companies-including Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others-are actively exploring new drugs to enhance the Stargardt Disease treatment landscape. Promising pipeline candidates in various stages of development include OCU410, KIO-301, Tinlarebant, and others.
*
Following a successful End-of-Phase 2 meeting with the FDA, Nanoscope Therapeutics plans to initiate a Phase 3 clinical trial for its optogenetic therapy, MCO-010, aimed at treating severe vision loss from Stargardt macular degeneration. Site selection is expected in Q4 2024, with patient dosing beginning in Q1 2025.
*
The FDA cleared SpliceBio's IND application for SB-007, a gene therapy targeting the genetic cause of Stargardt disease, with Phase 1/2 trials scheduled to start in 2025.
*
In December 2024, ViGeneron GmbH received FDA IND clearance for VG801, a novel mRNA trans-splicing gene therapy designed to treat Stargardt disease and other ABCA4-linked retinal dystrophies, enabling a Phase 1/2 trial to evaluate safety, tolerability, and initial efficacy.
*
In January 2024, the FDA cleared Ascidian Therapeutics' IND application and granted Fast Track designation for ACDN-01, the first clinical-stage RNA exon editor targeting the genetic cause of Stargardt disease. Enrollment for the Phase 1/2 STELLAR study is planned for the first half of 2024.
Stargardt Disease Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Stargardt Disease Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stargardt Disease treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Stargardt Disease market.
Download our free sample page report on Stargardt Disease pipeline insights [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Stargardt Disease Emerging Drugs
*
Tinlarebant: Belite Bio
*
KIO-301: Kiora Pharmaceuticals
*
OCU410: Ocugen
Stargardt Disease Companies
Over 20 leading companies are actively working on therapies for Stargardt Disease, with Belite Bio having a drug candidate that has reached the most advanced stage of development, Phase III.
DelveInsight's report covers around 20+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Stargardt Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Stargardt Disease Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Stargardt Disease Therapies and Key Companies: Stargardt Disease Clinical Trials and advancements [https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Stargardt Disease Pipeline Therapeutic Assessment
- Stargardt Disease Assessment by Product Type
- Stargardt Disease By Stage
- Stargardt Disease Assessment by Route of Administration
- Stargardt Disease Assessment by Molecule Type
Download Stargardt Disease Sample report to know in detail about the Stargardt Disease treatment market @ Stargardt Disease Therapeutic Assessment [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Stargardt Disease Current Treatment Patterns
4. Stargardt Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Stargardt Disease Late-Stage Products (Phase-III)
7. Stargardt Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Stargardt Disease Discontinued Products
13. Stargardt Disease Product Profiles
14. Stargardt Disease Key Companies
15. Stargardt Disease Key Products
16. Dormant and Discontinued Products
17. Stargardt Disease Unmet Needs
18. Stargardt Disease Future Perspectives
19. Stargardt Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Stargardt Disease Pipeline Reports Offerings [https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=stargardt-disease-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-belite-bio-ocugen-alkeus-pharmaceuticals-astellas-pharma-saliogen-therapeutics-asc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Stargardt Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Asc here
News-ID: 4162674 • Views: …
More Releases from ABNewswire
Couples Therapy Birmingham Support in Birmingham Expanded by Phinity Therapy to …
Couples Therapy Birmingham services have expanded across Frankley, Northfield, and Halesowen, improving access to professional relationship counselling for local residents. Phinity Therapy provides structured and confidential support for couples seeking guidance with communication challenges, conflict resolution, and long-term relationship wellbeing throughout the Birmingham region.
Introduction: Couples Therapy Birmingham in Birmingham
Couples Therapy Birmingham services are becoming more accessible to residents across Birmingham following the expansion of structured relationship support into Frankley, Northfield,…
UK Taxpayers Seek Easy Tax Software as Digital Filing Becomes the New Normal
As digital tax filing becomes the default across the UK, taxpayers are increasingly searching for easy tax software that removes complexity from self assessment and online submissions. With more people managing freelance income, property earnings, and side work alongside PAYE employment, demand for simpler tools is rising. Industry data from Pie shows sustained growth in users choosing guided, app-based tax platforms over manual forms and spreadsheets.
LONDON, United Kingdom - February…
Top CPA in Dallas, Texas, Advises Clients to Prepare for Potential Shifts in Tax …
Dallas, TX - With comprehensive tax reform proposals under consideration, taxpayers and business owners face a landscape of potential changes that could reshape financial strategies for years to come. The proposals encompass wide-ranging modifications to individual deductions, capital gains treatment, estate tax exemptions, and business tax structures that require proactive planning and careful evaluation.
Jeff Badu, a well-known tax accountant in Dallas, Texas [https://www.abnewswire.com/pressreleases/tax-professional-in-dallas-tx-highlights-importance-of-early-retirement-planning-as-many-approach-retirement-unprepared_785667.html], advises clients to review their current tax…
Top Plant Maintenance Contractor in Bay Area CA Notes Wave of Office Relocations …
Bay Area, CA - As commercial lease expirations accelerate through 2026, businesses across Silicon Valley are rethinking their office strategies. Companies are downsizing while simultaneously upgrading to class A office spaces featuring biophilic design elements that integrate nature into the workplace. This shift reflects a strategic response to the hybrid work era, where premium environments can make the difference in bringing employees back to the office.
Jennifer Farmer, a plant maintenance…
More Releases for Stargardt
Stargardt Disease Market Dynamics Indicate Upward Trajectory Through 2034, Repor …
The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United…
Stargardt Disease Market was valued at USD 120-150 million in 2024
Market Overview
The Stargardt Disease market is expanding steadily as advancements in retinal imaging, genetic testing, and gene-therapy research accelerate therapeutic development. Stargardt Disease, the most common form of inherited juvenile macular degeneration, is caused primarily by mutations in the ABCA4 gene and leads to progressive central vision loss.
The global market for Stargardt Disease diagnosis, management, and emerging therapeutics was valued at USD 120-150 million in 2024. With increasing clinical-trial activity…
Stargardt Disease Market to Witness Promising Upswing by 2034, DelveInsight Fore …
The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United…
Stargardt Disease Clinical Trials, Pipeline Insights, Treatment Drugs, and Compa …
DelveInsight's, "Stargardt Disease Pipeline Insight, 2024," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Stargardt Disease (STGD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Stargardt…
Stargardt Disease Pipeline, Clinical Trials, Emerging Therapies, and FDA Approva …
DelveInsight's, "Stargardt Disease Pipeline Insight 2023" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Stargardt Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from…
Global Juvenile Degeneration (Stargardt Disease) Market Forecast to 2025
Juvenile Degeneration (Stargardt Disease) Market report describes the thorough and collective examination of the Juvenile Degeneration (Stargardt Disease) industry during the past, present and conjecture periods. All the business verticals like driving market situation, regional Juvenile Degeneration (Stargardt Disease) nearness, and improvement openings are clarified. Top players of the Juvenile Degeneration (Stargardt Disease) industry, their business strategies, and growth opportunities are covered in this report. A report is incomplete without…
